Welcome to the Starpharma investor centre.Starpharma Holdings Limited is an Australian stock exchange listed biotechnology company with products based on its dendrimer technology platform. |
 |
 20 February 2012 Starpharma Interim Report and Half-year Financial ResultsStarpharma Holdings today released its interim report and financial results for the half-year ended 31 December 2011. Financial Results
|
 1 February 2012 Starpharma’s dendrimers improve efficacy of docetaxel in animals- Starpharma's dendrimer-docetaxel formulation significantly more effective than leading cancer drug docetaxel (Taxotere®) in breast cancer model - More than half (60%) of animals treated with Starpharma's dendrimer-docetaxel formulation had no evidence of tumour at 94 days whereas with docetaxel significant tumour regrowth was observed in all animals - Starpharma's dendrimer-docetaxel formulation improved water solubility by 5000-fold Read more |
 11 January 2012 SPL receives FDA Special Protocol Assessment for BV Phase 3Starpharma today announced that it has received final written agreement from the FDA on the design of its Phase 3 clinical studies of VivaGel® for the treatment of bacterial vaginosis (BV) under the FDA’s Special Protocol Assessment (SPA) scheme. The SPA is a binding declaration from the FDA that the Phase 3 clinical study design, endpoints, statistical analyses, and other aspects of the planned studies are acceptable to support regulatory approval of the product. Read more |
 20 December 2011 Shareholder Update: December 2011In this issue: › Starpharma raises $35m to advance pipeline › Starpharma signs with Ansell for condom coating › Putting a stop to stubborn BV: The VivaGel© solution › Clinical trials for VivaGel© gather pace › M&G invests $20 million › Dendrimers through the eyes of Professor Donald Tomalia
Download: Shareholder Update: December 2011 (pdf file, 628kb) Read more |
 19 December 2011 Starpharma's drug delivery program with Lilly advancesStarpharma today announced the advancement of its drug delivery collaboration with US pharmaceutical corporation Eli Lilly and Company. Read more |
8 December 2011 Starpharma SPP closes heavily oversubscribed; completing $35m financingStarpharma today announced that its Share Purchase Plan (SPP) which closed on Wednesday 7 December 2011, is oversubscribed by more than 400%. The SPP was capped at $3 million, and shareholders have subscribed a total in excess of $12 million. Read more |
|
16 November 2011 Starpharma completes A$32 million placement; SPP to followStarpharma is pleased to announce it has successfully raised A$32 million via a placement to international and domestic institutional, sophisticated and professional investors. It is intended to offer eligible existing shareholders the opportunity to also participate via a Share Purchase Plan to raise up to a further A$3 million. Read more |
6 September 2011 Starpharma elevated to S&P/ASX300 indexStarpharma has received notification that it will be elevated to the S&P/ASX 300 Index, effective from 19th September. Read more |
 22 August 2011 GSK Awarded Funds to Advance Dermal Treatment with Starpharma's DendrimersGlaxoSmithKline (GSK), and Starpharma today announced that GSK was awarded a grant to advance a dermal treatment based on Starpharma’s dendrimer drug delivery technology. The funds will be used to support Starpharma’s synthesis of dendrimer-based drug candidates which will then be tested by Stiefel, a GSK company with a view to further development towards a dermal product. Read more |
15 August 2011 Starpharma Commences Bacterial Vaginosis Prevention Study of VivaGel®Starpharma today announced the commencement of its Phase 2 study of VivaGel® for the prevention of bacterial vaginosis (BV), following receipt of ethics approval. Read more |
 29 June 2011 Starpharma advances leading cancer therapeutic in drug delivery programStarpharma today announced the nomination of leading anti-cancer drug docetaxel as a lead candidate in its cancer drug delivery program following encouraging early results.
|
23 May 2011 VivaGel® Demonstrates Efficacy in Bacterial VaginosisStarpharma today announced successful results of a major phase 2 clinical study that demonstrated efficacy of VivaGel® for the treatment of bacterial vaginosis (BV). Key Points:
|
Click here for financial reports archive
|
20 February 2012 Starpharma Interim Report and Half-year Financial ResultsStarpharma Holdings today released its interim report and financial results for the half-year ended 31 December 2011. Financial Results
|
 10 February 2012 Bioshares Report: Starpharma Takes Aim at DocetaxelThis Bioshares analysis provides insight into promising advancements within the Biotech sector in 2012. Starpharma is recognised for achieving a significant rise in shareprice and reaching exciting milestones in the development and pending commercialisation of its diverse research portfolio.
Download: Bioshares Issue 442 (pdf file, 27kb) |
|
11 November 2011 AGM Chairman's address & CEO presentation; Results of AGMStarpharma released its AGM Chairman's address and CEO presentation for the meeting held 10th November 2011. Results of voting were released following the meeting. Read more |
 29 August 2011 Annual Report and Full Year Financial ResultsStarpharma today released its annual report and financial results for the year ended 30 June 2011. Financial Results
|
Click here for more In the Media
 14 February 2012 Herald Sun: In the BlackHerald Sun Journalist John Beveridge details how biotechnology companies are working to ‘fix many ailments’, with specific reference to promising results emerging from Starpharma’s diverse research portfolio. The best thing about Starpharma is that it owns a genuine platform technology that is capable of spinning off multiple products across a range of different and highly lucrative areas. It owns a forest of patents on dendrimers—tiny polymers which can be engineered to create many different results, such as making a drug water soluble or preventing the transmission of viruses and bacteria. Chief executive Dr Jackie Fairley said the recent approval from the US Food and Drug Administration and European regulators for phase 3 trials of its VivaGel product later this year was a highly significant step in bringing the product to market. |
 8 February 2012 Australian Financial Review: Biotechs making a steady recoveryAustralian Financial Review Journalist Brendon Lau investigates how Australian biotech companies are attracting the attention of local and international investors. There is likely to be a sharp pick-up in interest in Australian biotechs this year as they move into their next phase of growth, which will pave the way for them to be taken over by global drug companies. Most of the capital is expected to be invested in the Australian market as our biotech sector is considered to be the most mature in the region following the resounding success of the likes of Mesoblast, Acrux and Starpharma Holdings, which have put Australia on the global biotech stage. Retail shareholders strongly oversubscribed for their entitlements at recent capital raisings by Alchemia, Phosphagenics and Starpharma – the latter two attracting new overseas professional and high net-worth investors. |
|
12 January 2012 Australian Financial Review: Starpharma's VivaGel step closer to marketAustralian Financial Review Journalist Carrie LaFrenz reports: Emerging biotech Starpharma Holdings has been given the tick of approval from the US Federal and Drug Administration on the design of its Phase 3 clinical studies for its key VivaGel product, taking it one step closer to market. Starpharma has a number of promising technologies and has caught the attention of some large investors. UK-based M&G Investments took a 6.7 per cent stake following the successful $32 million placement in November. |
 11 January 2012 Finance News Network: Starpharma gets binding agreement for VivaGelRebecca Richardson of Finance News Network presents on Starpharma's written agreement from the FDA on the design of its Phase 3 clinical studies of VivaGel® for the treatment of bacterial vaginosis (BV) under the FDA’s Special Protocol Assessment (SPA) scheme.
|
|
6 December 2011 Herald Sun: Small fry happy to follow the right movesHerald Sun Journalist John Beveridge takes a close look at why M&G made a significant investment in Starpharma and what it could mean for other buyers: ‘If you see a clever investor grabbing a stake in a company, there is no problem piggy-backing on their research and following them on board.’
Go to the article (external link) |
29 November 2011 Australian Financial Review: Funds pick up beaten down retailAustralian Financial Review Journalist Brendon Lau investigates the activity of fund managers across a number of key stocks: Emerging biotech Starpharma Holdings has also found itself in demand by institutional investors in the wake of its recent capital raising. The stock could re-rate, just as Mesoblast did, because M&G – one of the largest UK investment funds that is owned by Prudential Group – bought a 6.7 per cent stake in Starpharma. M&G also became a major shareholder in Mesoblast in December last year and the stock has rallied around 80 per cent since. |
 23 October 2011 ABC Radio Australia – Innovations: VivaGel Phase 3 Trial Gets Go-Ahead from FDAABC Radio Innovations Host Desley Blanch interviews Starpharma CEO Dr Jackie Fairley about the significance of Starpharma receiving FDA approval for the commencement of a Phase III clinical trial testing VivaGel for the treatment of Bacterial Vaginosis.
Go to the article (external link) |